We are here to assist you.
Health Advisor
+91-8877772277Available 7 days a week
10:00 AM – 6:00 PM to support you with urgent concerns and guide you toward the right care.
Explore the different types of kidney cancer, including Renal Cell Carcinoma (RCC) subtypes like clear cell, papillary, and chromophobe, as well as rarer forms like Wilms tumor and UTUC. Learn about diagnosis, treatment, and when to seek medical advice.

Understanding the Different Types of Kidney Cancer Kidney cancer, a serious health concern, refers to the uncontrolled growth of abnormal cells in one or both of your kidneys. While the term might sound singular, it encompasses a variety of subtypes, each with its own characteristics, treatment approaches, and prognosis. The most common form of kidney cancer is Renal Cell Carcinoma (RCC), which accounts for about 90% of all kidney cancers. RCC originates in the tiny tubules within the kidneys responsible for filtering blood and producing urine. However, RCC itself is not a single entity; it is further classified into several distinct subtypes based on the appearance of the cancer cells under a microscope. Understanding these differences is crucial for accurate diagnosis and effective treatment planning. Renal Cell Carcinoma (RCC) and Its Subtypes Renal Cell Carcinoma (RCC), also known as renal cell adenocarcinoma, is the primary type of kidney cancer affecting adults. It arises from the lining of the renal tubules. The specific subtype of RCC can significantly influence the course of the disease and how it responds to treatment. Clear Cell Renal Cell Carcinoma (ccRCC) This is the most prevalent subtype, making up approximately 70-80% of all RCC cases. Under a microscope, the cells of ccRCC appear clear or pale due to a high content of lipids and carbohydrates. The 5-year survival rate for clear cell RCC is around 70%, though this can vary based on the stage at diagnosis and other factors. Papillary Renal Cell Carcinoma (pRCC) Accounting for about 5-10% of RCC cases, papillary renal cell carcinoma is characterized by finger-like projections, known as papillae, formed by the cancer cells. This subtype often has a more favorable prognosis, with a 5-year survival rate of approximately 90%. Chromophobe Renal Cell Carcinoma This subtype constitutes about 5% of RCC cases. The cells in chromophobe RCC are typically pale and larger than those found in clear cell carcinoma. A notable characteristic is its tendency to metastasize less frequently, with only about 7% of chromophobe cancers spreading to other parts of the body, contributing to a better outlook. Sarcomatoid Renal Cancer Sarcomatoid features can occur in any subtype of RCC, but when they are the predominant cell type, it's referred to as sarcomatoid renal cancer. This aggressive subtype tends to grow rapidly and is often diagnosed at a more advanced stage compared to other RCC types. Clear Cell Papillary Renal Cell Carcinoma Making up about 1-4% of all kidney cancers, this subtype exhibits a mix of features from both clear cell and papillary RCC. It generally has a good prognosis, with reported 2-year survival rates exceeding 90%. Collecting Duct Renal Cell Carcinoma This is a rare and aggressive subtype, accounting for less than 1% of kidney tumors. It originates from the collecting ducts, which are tubes that transport urine from the nephrons to the renal pelvis. The prognosis for collecting duct carcinoma is often poor, with about half of affected individuals living fewer than 12 months. Medullary Renal Cell Carcinoma Also known as SMARCB1-deficient renal medullary carcinoma, this type most commonly affects individuals of African descent who have sickle cell disease or other sickle cell-related blood conditions. It is a particularly aggressive form of kidney cancer. Mucinous Tubular and Spindle Cell Carcinoma (MTSCC) MTSCC is a low-grade cancer that is thought to comprise less than 0.8% of all kidney cancers. Under microscopic examination, its cancer cells appear tubular, merging with spindle-shaped projections. Multilocular Cystic Renal Cell Carcinoma This subtype accounts for about 3.1-6% of RCC cases. It is characterized by multiple cysts within the kidney and generally has an excellent outlook. Other Types of Kidney Cancer While RCC and its subtypes are the most common, other forms of kidney cancer exist: Wilms Tumor This is the most common type of kidney cancer in children, rarely occurring in adults. It is a distinct type of cancer that requires specialized pediatric oncology care. Upper Urinary Tract Urothelial Carcinoma (UTUC) Previously known as transitional cell cancer of the kidney or ureter, UTUC originates in the transitional cells lining the renal pelvis (the part of the kidney that collects urine) and the ureter (the tube that carries urine to the bladder). This cancer shares similarities with bladder cancer. Sarcoma of the Kidney (Renal Sarcoma) Renal sarcomas are rare cancers that arise from the connective tissues of the kidney, such as blood vessels or smooth muscle. They are distinct from RCC and are treated differently. Kidney Metastasis This is not a primary kidney cancer but rather cancer that has spread to the kidneys from another part of the body, such as the lungs, breast, or gastrointestinal tract. Treatment focuses on the primary cancer and managing symptoms in the kidneys. Diagnosis and When to Consult a Doctor Diagnosing kidney cancer involves a combination of medical history, physical examination, and various tests, including imaging studies (like CT scans, MRIs, and ultrasounds) and biopsies. Early detection is key to improving outcomes. If you experience persistent symptoms such as blood in your urine, a persistent ache in your side or back, a lump or mass in your side or abdomen, fatigue, or unexplained weight loss, it is essential to consult a doctor promptly. Discussing any concerns with your healthcare provider will allow for timely evaluation and appropriate management. Treatment and Prevention Treatment for kidney cancer depends heavily on the type, stage, and grade of the cancer, as well as the patient's
In summary, timely diagnosis, evidence-based treatment, and prevention-focused care improve long-term health outcomes.
Learn about potential side effects of CML treatments like TKIs, interferon, chemotherapy, and stem cell transplants. Understand what to expect and how to communicate with your doctor for effective management.
April 1, 2026

Discover essential support resources, financial aid options, and community connections for individuals navigating life with Chronic Myeloid Leukemia (CML). Find practical advice and empathetic guidance.
April 1, 2026
Explore targeted therapy for multiple myeloma. Learn how these precision treatments work, their types, potential side effects, and how they're used alongside other therapies to manage this blood cancer.
April 1, 2026